Plexium Company
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas.
Founded Date:
2018-01-01
Last Funding Date:
2025-08-25
Industry:
Quantum Chemistry
Total Funding:
225115703
Headquarters:
San Diego,California,United States,North America
Employee Number:
51-100
Funding Status:
private
Super Industry:
Quantum Science Applications
Funding Stage:
Late Stage Venture
Funding Total Value:
225115703
Last Funding Total Usd:
60115703
Last Funding Total Currency:
USD
Last Funding Total Value:
60115703
Founders:
Andrew MacConnell,Joe Rokicki